Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.38 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380625 | 0.93 | ALDH1A1 (0.41) | ALDH1A1CHRM2CHRM3HSD11B1NPC1L1 | |
| SCHEMBL2381415 | 0.88 | NPC1L1 (0.45) | ALDH1A1CHRM2CHRM3NPC1L1LMNA | |
| SCHEMBL2311931 | 0.84 | OPRM1 (0.42) | ALDH1A1CHRM2CHRM3MEN1KMT2A | |
| SCHEMBL2309710 | 0.83 | HDAC2 (0.41) | ALDH1A1HSD11B1 | |
| SCHEMBL2310822 | 0.82 | HSD11B1 (0.44) | ALDH1A1HSD11B1MEN1KMT2A | |
| SCHEMBL2312090 | 0.81 | CACNA2D1 (0.55) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2381294 | 0.81 | L3MBTL1 (0.48) | ALDH1A1HSD11B1NPC1L1LMNAL3MBTL1 | |
| SCHEMBL2311074 | 0.80 | RAB9A (0.46) | ALDH1A1NPC1L1CHRM4 | |
| SCHEMBL2307819 | 0.80 | OPRM1 (0.51) | CHRM2CHRM3HSD11B1LMNAMEN1 | |
| SCHEMBL2306085 | 0.80 | OPRM1 (0.51) | CHRM2CHRM3HSD11B1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | claimed |
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1D, CACNA1S | ALDH1A1 575/4885CHRM2 292/4885CHRM3 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.